TOCA - Tocagen: A Valuation
Tocagen Inc. (TOCA) is a clinical-stage company engaged in developing selective gene therapy for various cancers. The company's platform uses retroviral replicating vectors technology and its lead drug candidate is a combo of Toca 511 and Toca FC in Phase III clinical trial targeting recurrent high-grade glioma. We recently covered Tocagen in a report. This valuation article is a follow up. The Valuation sheet is available here.
The valuation sheet for the company stock is divided into three sheets where Actuals provide the annual financials for the past two years. ISBS sheet shows